FTC, Catalent and Novo Holdings
Novo Holdings' $16.5B Catalent buyout in crosshairs as consumer groups ask FTC to block the deal
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. | A dozen consumer groups and trade unions penned a letter to Lina Khan,
After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...
This week marked the start of the third-quarter earnings season, with Johnson & Johnson exceeding Wall Street’s expectations.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Paul Harris of Harris Douglas Asset Management says he hasn’t sold a stock since 2020. ‘I don’t feel the need to sell ...
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and ...
Novo Nordisk NVO has outperformed the market over the past 10 years by 6.26% on an annualized basis producing an average ...
Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback